All human genes undergo alternative splicing leading to the diversity of the proteins. However, in some cases, abnormal regulation of alternative splicing can result in diseases that trigger defects in metabolism, reduced apoptosis, increased proliferation, and progression in almost all tumor types. Metabolic dysregulations and immune dysfunctions are crucial factors in cancer. In this respect, alternative splicing in tumors could be a potential target for therapeutic cancer strategies. Dysregulation of alternative splicing during mRNA maturation promotes carcinogenesis and drug resistance in many cancer types. Alternative splicing (changing the target mRNA 3'UTR binding site) can result in a protein with altered drug affinity, ultimately leading to drug resistance.. Here, we will highlight the function of various alternative splicing factors, how it regulates the reprogramming of cancer cell metabolism, and their contribution to tumor initiation and proliferation. Also, we will discuss emerging therapeutics for treating tumors via abnormal alternative splicing. Finally, we will discuss the challenges associated with these therapeutic strategies for clinical applications.

An intricate rewiring of cancer metabolism via alternative splicing / Temaj, Gazmend; Chichiarelli, Silvia; Saha, Sarmistha; Telkoparan-Akillilar, Pelin; Nuhii, Nexhibe; Hadziselimovic, Rifat; Saso, Luciano. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 217:(2023), p. 115848. [10.1016/j.bcp.2023.115848]

An intricate rewiring of cancer metabolism via alternative splicing

Chichiarelli, Silvia
;
Saso, Luciano
2023

Abstract

All human genes undergo alternative splicing leading to the diversity of the proteins. However, in some cases, abnormal regulation of alternative splicing can result in diseases that trigger defects in metabolism, reduced apoptosis, increased proliferation, and progression in almost all tumor types. Metabolic dysregulations and immune dysfunctions are crucial factors in cancer. In this respect, alternative splicing in tumors could be a potential target for therapeutic cancer strategies. Dysregulation of alternative splicing during mRNA maturation promotes carcinogenesis and drug resistance in many cancer types. Alternative splicing (changing the target mRNA 3'UTR binding site) can result in a protein with altered drug affinity, ultimately leading to drug resistance.. Here, we will highlight the function of various alternative splicing factors, how it regulates the reprogramming of cancer cell metabolism, and their contribution to tumor initiation and proliferation. Also, we will discuss emerging therapeutics for treating tumors via abnormal alternative splicing. Finally, we will discuss the challenges associated with these therapeutic strategies for clinical applications.
2023
Alternative splicing; cancer; metabolism
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
An intricate rewiring of cancer metabolism via alternative splicing / Temaj, Gazmend; Chichiarelli, Silvia; Saha, Sarmistha; Telkoparan-Akillilar, Pelin; Nuhii, Nexhibe; Hadziselimovic, Rifat; Saso, Luciano. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 217:(2023), p. 115848. [10.1016/j.bcp.2023.115848]
File allegati a questo prodotto
File Dimensione Formato  
Temaj_An intricate_2023.pdf

solo gestori archivio

Note: 2023_Alternative_Splicing (Review)
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1691216
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact